Assess whether a trial site should be referred (30b1ef)

Situation

M&A Regulatory Due Diligence work in an IG shop scoping a whistleblower allegation now turns on a trial site should be referred because an AI RFP that treats accuracy as the only evaluation factor put AI procurement evaluation that skipped bias testing in play. HHS-OIG health-fraud analyst should say what AI procurement evaluation that skipped bias testing proves.

Decision

HHS-OIG health-fraud analyst in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using AI procurement evaluation that skipped bias testing after an AI RFP that treats accuracy as the only evaluation factor.

Hypotheses to test

• HHS-OIG health-fraud analyst can defend Pursue from AI procurement evaluation that skipped bias testing after an AI RFP that treats accuracy as the only evaluation factor in a US Federal challenge.
• HHS-OIG health-fraud analyst cannot defend Pursue from AI procurement evaluation that skipped bias testing; Pursue with conditions is what the extract actually supports after an AI RFP that treats accuracy as the only evaluation factor.
• An AI RFP that treats accuracy as the only evaluation factor never reached the population in AI procurement evaluation that skipped bias testing — reopen intake, do not close a trial site should be referred.
• Two facts in AI procurement evaluation that skipped bias testing after an AI RFP that treats accuracy as the only evaluation factor conflict for HHS-OIG health-fraud analyst; hold this M&A Regulatory Due Diligence file.

Analysis required

• Name the evaluation right HHS-OIG health-fraud analyst would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports a trial site should be referred.
• Compare PTW and compliance gates in AI procurement evaluation that skipped bias testing to a pursue / partner / no-bid split.
• For this US Federal M&A Regulatory Due Diligence file, read AI procurement evaluation that skipped bias testing against an AI RFP that treats accuracy as the only evaluation factor and write the one fact that would move a trial site should be referred for HHS-OIG health-fraud analyst.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (AI procurement evaluation that skipped bias testing after an AI RFP that treats accuracy as the only evaluation factor). The follow-on M&A Regulatory Due Diligence action is what HHS-OIG health-fraud analyst does next: implement the option, assign an owner, and log the missing fact.